Mechanical thrombectomy has demonstrated clinical benefit in acute ischemic stroke caused by anterior-circulation large-vessel occlusion, but several biological levels can remain separated. Reopening the parent artery is not identical to angiographic reperfusion, adequate tissue-level perfusion, restored microvascular flow, preserved oxygen delivery or neurological recovery. After recanalization, downstream vessels may remain hypoperfused, exhibit uneven capillary flow or shunting, become hyperperfused through failed autoregulation, leak across the blood–brain barrier, or be compressed by edema. The review therefore treats incomplete tissue-level reperfusion as an intermediate imaging and tissue phenotype between technical success and clinical outcome. It emphasizes that temporally aligned measurements are needed to test whether particular biological processes precede or accompany the observed perfusion abnormalities.

The endothelial glycocalyx occupies the luminal surface of blood vessels and includes glycosaminoglycans, membrane-bound proteoglycans, glycoproteins and associated plasma proteins. Its composition and thickness vary by vascular bed, flow state, inflammation, age and disease context. In the brain, it operates within the specialized blood–brain barrier and neurovascular unit, alongside endothelial cells, pericytes, basement membrane, astrocytic endfeet, microglia, neurons and extracellular matrix. The glycocalyx is related to, but not synonymous with, either the blood–brain barrier or the neurovascular unit. An intact layer can limit direct contact between circulating cells and the endothelial membrane, support antithrombotic and anticoagulant surface properties, regulate permeability and participate in shear-dependent nitric-oxide signaling. Experimental cerebral ischemia work links glycocalyx integrity to suppression of endothelial transcytosis and preservation of barrier function, while brain-aging research links glycocalyx dysregulation and mucin-domain glycoproteins to blood–brain barrier stability. These findings strengthen the anatomical rationale for examining the layer after thrombectomy but do not establish that its disruption causes human post-thrombectomy no-reflow.

The proposed two-stage model begins with reduced endothelial-surface resilience. In this review, cardiometabolic vulnerability is a conceptual host context rather than a diagnosis: chronic metabolic, inflammatory, renal and vascular stress may reduce baseline resilience before the ischemic event. Cross-disease vascular evidence associates diabetes and hyperglycemia with oxidative and inflammatory stress and impaired nitric-oxide availability, and hypertension and dyslipidemia with altered mechanotransduction, abnormal hemodynamic stress and inflammatory activation. Renal dysfunction may influence systemic endothelial homeostasis, inflammation and clearance of circulating glycocalyx-related biomarkers, but that relationship has not been validated as a cerebral post-thrombectomy mechanism. Experimental and translational brain evidence also supports aging-related alterations in glycocalyx-associated barrier biology. Indirect clinical studies link cardiometabolic risk states to unfavorable outcomes after endovascular therapy, although they do not identify glycocalyx injury as the operating pathway. The two-stage hypothesis therefore proposes that pre-existing vulnerability may lower the capacity to withstand ischemic and reperfusion-related stress, while acute occlusion adds endothelial hypoxia, ATP depletion, acidosis, ionic dysregulation, low shear and inflammatory signaling before the artery is reopened.

Several acute triggers could converge on the vulnerable luminal interface. Restoration of oxygen and substrate produces abrupt shear changes, reactive oxygen species, leukocyte recruitment, thrombin generation and cytokine signaling that may promote enzymatic shedding of glycocalyx components. Complement activation contributes to cerebral ischemia–reperfusion injury in experimental models, while experimental thrombectomy models implicate succinate-associated metabolic injury, but neither process is specific to the glycocalyx. Stent retrievers, aspiration catheters, repeated passes, clot–device interaction and rapid flow restoration can perturb the vessel wall and endothelium; direct visualization of cerebral glycocalyx damage from these devices in patients remains unavailable. Distal clot migration or residual microemboli can also create patchy low-flow territories and sustain thromboinflammation. These processes may occur upstream, downstream, in parallel with or independently of glycocalyx dysfunction, supporting a network model rather than a single linear cascade.

Loss of the glycocalyx’s normal functions could amplify established no-reflow mechanisms. By separating leukocytes from endothelial adhesion platforms, an intact layer discourages rolling, adhesion and capillary stalling. In a mouse recanalization model, neutrophils obstructed a substantial fraction of capillaries after upstream flow was restored, supporting leukocyte plugging as a no-reflow mechanism, but the experiment did not establish glycocalyx shedding as the initiating event in human thrombectomy. Glycocalyx disruption could also expose procoagulant surfaces and reduce local antithrombotic capacity, potentially contributing to platelet adhesion, fibrin deposition and microthrombosis. Primary experimental stroke work has demonstrated capillary fibrin deposition and stacked erythrocytes after recanalization or thrombolysis, supporting a thrombotic component of no-reflow, while the share attributable specifically to cerebral glycocalyx dysfunction remains unknown.

Other proposed interactions involve mechanosensing, barrier stability and capillary-flow distribution. Because glycocalyx-dependent mechanotransduction links shear stress to endothelial nitric-oxide production, surface damage could make endothelial sensing of restored flow more heterogeneous and potentially contribute to vasomotor mismatch or impaired autoregulation. Imaging of cerebrovascular reactivity after successful endovascular treatment supports persistent hemodynamic dysfunction, but it does not identify glycocalyx causality. Experimental stroke studies associate glycocalyx disruption with increased endothelial transcytosis and blood–brain barrier permeability, while human thrombectomy imaging associates barrier disruption or increased permeability with edema, hemorrhagic transformation and adverse tissue states; neither evidence type is glycocalyx-specific. Pericyte-mediated capillary constriction is well supported experimentally after cerebral ischemia, yet direct coupling between glycocalyx injury and pericytes after thrombectomy has not been demonstrated. Theoretical and imaging work also indicates that heterogeneous capillary transit can impair oxygen extraction even when total cerebral blood flow is not uniformly reduced. Patchy adhesion, microthrombosis, vasomotor mismatch and barrier leakage are possible contributors, but perfusion-metabolic validation is required in thrombectomy populations.

Human biomarker studies do not yet resolve these questions. Syndecan-1, heparan sulfate and hyaluronan can be sampled repeatedly and may reflect shedding products from endothelium, but peripheral concentrations are not brain-specific. They can also derive from the lung, kidney, liver, gut, systemic inflammation, clearance and vascular instrumentation. Paired intracranial and peripheral sampling in large-vessel occlusion cohorts has shown spatial and temporal heterogeneity in syndecan-1, indicating that local distal-occlusion signals and peripheral venous concentrations cannot be assumed to be synchronized. Longitudinal endovascular-therapy and thrombectomy cohorts also show that syndecan-1 behavior depends on sampling time and clinical context. A thrombolysis-treated cohort found higher plasma syndecan-1 associated with unfavorable outcome, whereas a mechanical-thrombectomy cohort reported that lower postoperative-day-1 syndecan-1 was associated with worse prognosis. Prospective 2026 measurements before recanalization and at 24 and 48 hours found treatment-group differences across serial assessments but no direct association between syndecan-1 and either the National Institutes of Health Stroke Scale or the modified Rankin Scale. These divergent results show why an isolated circulating concentration cannot be translated directly into “more” or “less” cerebral glycocalyx injury.

Evidence that downstream microcirculation remains therapeutically actionable does not validate a glycocalyx-specific explanation. The phase 2b CHOICE trial suggested a higher frequency of excellent outcome with intra-arterial alteplase after successful thrombectomy, although it was stopped early and requires replication. The PEARL study subsequently reported a higher proportion of 90-day modified Rankin Scale scores of 0–1 with intra-arterial alteplase after successful endovascular reperfusion in selected patients. Phase 1b/2a data on intra-arterial tenecteplase support dose selection and safety for further study but do not establish definitive efficacy. These trials support the therapeutic actionability of the post-endovascular microcirculation; they do not establish glycocalyx repair as the operative mechanism. Strategies directed at oxidative stress, complement activation, metabolic stress, endothelial inflammation, blood–brain barrier dysfunction, edema, glucose control, blood-pressure variability and systemic inflammatory burden may influence the luminal endothelial surface indirectly, but their effects are pleiotropic and cannot be labeled glycocalyx-specific. Sulodexide, heparanase-related strategies, glycosaminoglycan restoration and preservation of hyaluronan or heparan sulfate are conceptually relevant interventions, yet supporting evidence comes mainly from diabetes, sepsis, non-cerebral vascular injury, animal models or endothelial-cell systems. They remain experimental, cross-disease or trial-enabling candidates rather than validated post-thrombectomy treatments.

The authors propose a prospective cohort of adults with anterior-circulation large-vessel occlusion who achieve near-complete or complete angiographic reperfusion after mechanical thrombectomy. Serial blood samples would be collected before treatment, immediately after recanalization, one to six hours later and at 24 hours, with local arterial sampling only where technically and ethically feasible. Biomarker trajectories would be aligned with immediate or early perfusion imaging, blood–brain barrier assessments, 24-hour final infarct volume and infarct growth, edema, hemorrhagic transformation, early neurological status and 90-day functional outcome. Researchers would prespecify an imaging-defined incomplete-reperfusion phenotype, such as abnormal parenchymal contrast-transit delay after final angiographic reperfusion or residual perfusion abnormality one to six hours after thrombectomy, and test a pathway from biomarker dynamics to impaired microvascular reperfusion, tissue-injury expansion and clinical outcome. Cardiometabolic factors would be modeled as confounders and potential effect modifiers, while competing mechanisms such as distal embolization, microthrombosis, pericyte contraction, endothelial swelling, complement activation and inflammation would be examined in parallel.

The review synthesizes targeted English-language literature available through 30 April 2026 from PubMed/MEDLINE, Web of Science, Embase and Google Scholar. Its final set contains 53 publications, including 38 primary clinical, experimental or modeling reports and 15 reviews, meta-analyses or narrative papers. The authors separated direct human thrombectomy evidence from indirect biomarker and imaging studies, experimental cerebral evidence, cross-disease vascular evidence and hypothesis-generating inference. Because this was a narrative review rather than a systematic review or meta-analysis, it did not include a PRISMA workflow, formal risk-of-bias assessment or prospectively retained record-level screening counts. The framework therefore cannot claim systematic completeness or causal certainty. Its near-term value is to specify experiments that could support, refine or reject the hypothesis: serial, compartment-annotated biomarkers, temporally aligned perfusion and barrier imaging, tissue endpoints and explicit modeling of host vulnerability and competing mechanisms. Until direct cerebral imaging and tightly timed human studies establish the sequence of events, glycocalyx dysfunction remains a biologically plausible amplifier and organizing research framework, not an established cause or a ready-made therapeutic target.

Subject of Research: Endothelial glycocalyx dysfunction as a proposed amplifier of microvascular reperfusion failure after mechanical thrombectomy

Article Title: Endothelial glycocalyx dysfunction in the setting of mechanical thrombectomy: a conceptual link between cardiometabolic vulnerability and microvascular reperfusion failure

Article References: Wu, X., Mi, S., Ma, J., Xing, Y., Li, G., Cao, Z., & Xiong, X. (2026). Endothelial glycocalyx dysfunction in the setting of mechanical thrombectomy: a conceptual link between cardiometabolic vulnerability and microvascular reperfusion failure. Frontiers in Neurology, 17, Article 1919445. https://doi.org/10.3389/fneur.2026.1919445

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1919445

Keywords: mechanical thrombectomy, endothelial glycocalyx, microvascular reperfusion, no-reflow, acute ischemic stroke, cardiometabolic vulnerability, syndecan-1, blood–brain barrier, narrative review, Endothelial, glycocalyx, dysfunction

The editorial, authored by Gabriel Broocks of Helios Medical Center Schwerin and colleagues from Germany, Singapore, and the United States, synthesizes the current state of DMVO research across epidemiology, diagnostics, treatment options, and outcome prediction. Its central message is that DMVO is not a single disease entity. Occlusions differ in vessel diameter, anatomical segment, eloquence of the affected territory, collateral supply, clinical deficit severity, thrombus origin, and procedural accessibility. Primary DMVOs must also be distinguished from secondary distal occlusions that arise through spontaneous or treatment-related thrombus migration after an initially proximal occlusion. Treating all of these presentations as one therapeutic indication, the authors contend, has been a fundamental error in trial design.

Three randomized trials have now tested routine thrombectomy in broadly selected DMVO populations. DISTAL, ESCAPE-MeVO, and the early-terminated DISCOUNT trial did not demonstrate a clinical benefit of endovascular treatment and raised concerns regarding procedure-related harm, including symptomatic intracranial hemorrhage and, in some cohorts, mortality signals. These results sent shockwaves through the stroke community, prompting some to question whether distal thrombectomy should be abandoned altogether. But the story took a dramatic turn with ORIENTAL-MeVO, a trial conducted in Chinese patients with medium-vessel occlusion and moderate-to-severe deficits. Among participants with a National Institutes of Health Stroke Scale score of 6 or higher, endovascular treatment increased 90-day functional independence from 46.6 percent to 58.6 percent, with an adjusted rate ratio of 1.24 and a 95 percent confidence interval of 1.07 to 1.44. Symptomatic intracranial hemorrhage occurred in 4.7 percent of treated patients versus 2.2 percent of controls. This divergent result underscores the influence of trial population, occlusion definition, thrombolysis use, and procedural strategy, and argues powerfully against treating DMVO as a single therapeutic indication.

Neutral treatment effects should not be mistaken for a benign natural history. Across contemporary randomized control groups, between 32 and 53 percent of medically managed patients did not achieve functional independence at 90 days. This proportion exceeded 45 percent in DISTAL, at 45.3 percent, and in ORIENTAL-MeVO, at 53.4 percent. These control arms represent some of the most robust prospective repositories of outcome data under contemporary medical care, and they show that DMVO frequently results in death or persistent dependency. The observation does not justify indiscriminate thrombectomy, since technical accessibility alone does not establish a treatment indication and expected benefit must exceed procedural risk. But it does demonstrate that both routine endovascular treatment as tested and medical treatment alone remain unsatisfactory for many patients, reinforcing the urgent need for better selection and safer or more effective reperfusion strategies.

The trials, therefore, sharpen rather than settle the central question of patient selection, particularly for M2 occlusions, whose anatomical and functional definitions remain heterogeneous. Proximal or dominant M2 branches lie closer to classical large-vessel-occlusion evidence than truly distal M3, A3, or P3 occlusions. Observational data suggest that any benefit of successful reperfusion may concentrate in specific phenotypes. In M2 stroke, the association between recanalization and 90-day functional independence was larger at higher baseline stroke severity, according to a multicenter cohort study published in Neurology. Complementing this, penumbral imaging identified subgroups defined by larger hypoperfusion or penumbral volumes in which reperfusion was associated with better outcome, as reported in the journal Stroke. These hypothesis-generating findings support imaging- and severity-informed selection rather than a purely anatomical indication, suggesting that the future of DMVO treatment lies not in the catheter itself but in the brain imaging that determines who receives it.

Several contributions to the Research Topic address the delicate balance between reperfusion efficacy and vessel safety. A systematic review and meta-analysis by Loh and colleagues found that combined stent-retriever and aspiration techniques were associated with higher first-pass reperfusion and lower symptomatic intracranial hemorrhage than single-device approaches, although final functional outcomes were similar. These retrospective data concern technique selection among treated patients and do not establish superiority of thrombectomy over medical treatment. The ONE-SEG technique of Hamada and colleagues, which combines limited deployment of the distal basket segment of a stent retriever with aspiration, achieved high reperfusion rates in a small M2 cohort, with outcomes differing substantially between primary and secondary M2 occlusions. On the engineering side, Ishiguro and colleagues linked reduced radial and axial device forces to less vessel deformation on bench testing and a lower frequency of post-procedural subarachnoid hemorrhage. When the expected absolute benefit is small, such reductions in procedural trauma may prove decisive.

Newer low-profile devices may alter the procedural risk-benefit balance, although their clinical relevance remains uncertain. In a retrospective series, the small-bore Red43 distal aspiration catheter showed high target-vessel trackability and reperfusion rates without symptomatic intracranial hemorrhage, perforation, or dissection. For stent-retriever thrombectomy, the randomized DISTALS trial specifically evaluated the radially adjustable low-profile Tigertriever 13 and reported favorable technical efficacy and safety, though these device-specific angiographic findings should not be equated with established functional benefit. A complementary strategy is local pharmacological reperfusion. The RESCUE-TNK trial was designed to evaluate intra-arterial tenecteplase for primary or secondary medium-vessel occlusions considered unsuitable for mechanical clot retrieval. These developments support comparative evaluation of device- and drug-specific reperfusion strategies using clinical rather than purely angiographic endpoints, a shift that could fundamentally change how the field measures success.

Anatomical and clinical heterogeneity is equally central to the DMVO puzzle. In an endovascular-treated cohort of isolated posterior cerebral artery occlusions, van Landeghem and colleagues observed that P1 occlusions produced more severe and broader deficits, whereas P2 occlusions more often caused visual syndromes that may be underrepresented by the NIHSS. Deep infarction remained common despite angiographic reperfusion, a finding that challenges the assumption that successful recanalization always translates into tissue salvage. The case series by Xu and Yang illustrates the diagnostic complexity of bilateral paramedian thalamic infarction and the artery of Percheron, in which a unilateral fetal-type posterior cerebral artery may serve as an anatomical clue and treatment targeted upstream large-vessel pathology rather than the perforator itself. The Research Topic also examines markers of adverse outcome after reperfusion. A meta-analysis by Wu and colleagues associated early venous filling during thrombectomy with higher intracranial hemorrhage risk and lower functional independence, a potentially useful real-time warning sign that still requires standardized definition and prospective validation.

The next phase of DMVO research should move beyond a binary debate over whether distal thrombectomy is safe and effective. Future studies should identify treatment-responsive phenotypes by integrating disabling deficit, eloquent tissue involvement, occlusion segment, collateral and perfusion status, thrombus characteristics, procedural accessibility, and predicted device-related risk, while separating primary from secondary DMVO. Outcome measures should capture vision, language, cognition, fine motor function, and quality of life in addition to the modified Rankin Scale, the standard but admittedly blunt instrument for measuring stroke recovery. The neutral randomized trials appropriately challenge indiscriminate treatment, and together with the positive ORIENTAL-MeVO signal, they sharpen two essential questions: which carefully selected patients can achieve a meaningful net benefit from rapid complete reperfusion, and how future trials should be designed to identify the patients most likely to benefit from endovascular treatment. For now, the answer lies not in the catheter but in the convergence of advanced imaging, refined phenotyping, and a willingness to abandon the one-size-fits-all approach that has defined the field for too long.

Subject of Research: Endovascular treatment and patient selection in distal medium vessel occlusion stroke

Article Title: Editorial: Distal, medium vessel occlusion stroke: epidemiology, diagnostics, treatment options, and outcome prediction

Article References: Broocks, G., Papanagiotou, P., Yeo, L. L. L., Gopinathan, A., Raz, E., & Meyer, L. (2026). Editorial: Distal, medium vessel occlusion stroke: epidemiology, diagnostics, treatment options, and outcome prediction. Frontiers in Stroke, 5, Article 1967379. https://doi.org/10.3389/fstro.2026.1967379

Image Credits: AI Generated

DOI: 10.3389/fstro.2026.1967379

Keywords: stroke, mechanical thrombectomy, medium vessel occlusion, endovascular treatment, randomized trials, M2 occlusion, penumbral imaging, intracranial hemorrhage, reperfusion, patient selection, NIHSS, functional independence

Now a prospective real-world study from Da Nang Hospital in Vietnam, published in Frontiers in Neurology, offers one of the clearest quantitative answers to date on how much of thrombectomy’s benefit operates through preventing this catastrophic swelling. The research team, led by Thien Quang Le and Nhan Duc Le, with collaborators at Washington University, Oxford, Harvard-affiliated hospitals and Toronto Metropolitan University, enrolled 202 consecutive patients with anterior-circulation large-vessel occlusion, stroke severity of at least 6 on the National Institutes of Health Stroke Scale, an Alberta Stroke Program Early CT Score of 5 or below, and admission within 24 hours of onset. Crucially, patients were selected using only non-contrast CT and CT angiography, a simplified workflow deliberately chosen because perfusion imaging is unavailable in much of the world where the global stroke burden is heaviest.

The study’s primary endpoint was deliberately pragmatic. Rather than relying on quantitative edema biomarkers that require dedicated post-processing software, the team defined severe cerebral edema as clinically significant mass effect: a maximum midline shift of at least 5 millimeters on follow-up imaging within 72 hours. This threshold is not arbitrary. A shift of 5 millimeters or more is widely used as a trigger for intensified neurological monitoring, osmotherapy, and consideration of decompressive hemicraniectomy, and it can be measured reliably on routine CT at the bedside in any emergency department. Of the 202 patients, 119 underwent thrombectomy while 83 received medical management alone, and the two groups differed substantially at baseline, with the medically managed patients being older, more severely affected, presenting later, and carrying larger infarcts on admission CT.

To untangle this pronounced selection bias, the investigators applied inverse probability of treatment weighting with doubly robust adjustment, a statistical technique that reweights the observational cohort to mimic the balance of a randomized trial. After weighting, baseline differences in age, sex, admission severity, infarct extent, and time from onset collapsed to standardized mean differences below 0.03. The results were striking. Mass effect developed in 31.1 percent of thrombectomy patients compared with 51.8 percent of medically managed patients, an adjusted odds ratio of 0.28, meaning clot removal cut the odds of dangerous swelling by roughly three-quarters. The median maximum midline shift was 0 millimeters in the thrombectomy group versus 5 millimeters under medical management. Favorable outcome, defined as independence or mild disability at 90 days on the modified Rankin Scale, was achieved by 47.1 percent of thrombectomy patients versus 19.3 percent of the comparison group, with an adjusted odds ratio of 2.32. Ninety-day mortality was 30.3 percent versus 50.6 percent, and early neurological deterioration was also significantly reduced. Symptomatic intracranial hemorrhage, assessed by SITS-MOST criteria, did not differ between groups, addressing a central safety concern.

The study’s most consequential contribution, however, lies in its causal mediation analysis, a statistical framework that decomposes a total treatment effect into direct and indirect pathways. The team asked a precise question: how much of thrombectomy’s functional benefit flows through preventing severe edema? The answer was approximately 29.5 percent in the intention-to-treat comparison and 29.0 percent in an as-treated analysis comparing good reperfusion, defined as mTICI 2b or better, against poor reperfusion. The as-treated comparison functions as a natural experiment internal to the cohort, and there the indirect pathway reached formal statistical significance. Notably, the proportion mediated rose monotonically as the outcome threshold captured more severe disability, reaching 41.5 percent at a modified Rankin Scale score of 4 or worse. In other words, preventing malignant swelling is most prominent in averting the worst outcomes: severe disability and death.

These estimates converge remarkably with independent analyses using entirely different edema metrics. In the randomized TENSION trial, approximately 34 percent of thrombectomy’s improvement in 90-day outcome was associated with reduced net water uptake, a densitometric measure that directly quantifies tissue water content within the infarct, while only 14 percent was attributable to change in lesion extent. An analysis of the MAGIC registry found that incorporating malignant cerebral edema attenuated the reperfusion-outcome coefficient by roughly 32.5 percent. By contrast, a mediation analysis of the HERMES dataset had found that reduction of follow-up infarct volume explained only 12 percent of thrombectomy’s clinical benefit. The directional agreement across methodologically distinct cohorts suggests that edema attenuation is a generalizable pathway of reperfusion benefit, and one that accounts for a larger share of that benefit than final infarct volume reduction. Edema prevention and infarct limitation therefore appear to represent distinct, partly independent components of the treatment effect, with a substantial remainder operating through penumbral salvage, blood-brain barrier preservation, and metabolic restoration.

The findings also help reconcile an apparent contradiction in the literature. Secondary analyses from the SELECT2 and ANGEL-ASPECT trials had reported seemingly increased midline shift after thrombectomy in patients with very large cores, creating uncertainty about whether reperfusion might actually worsen swelling. The Da Nang team’s interpretation draws on the bimodal response hypothesis from the HERMES meta-analysis: reperfusion was not associated with greater edema overall but did exacerbate swelling in patients with extremely extensive established ischemia, while remaining beneficial in moderate-large cores with salvageable penumbra. Mechanistically, cerebral edema after large-vessel occlusion develops in overlapping stages. In the first hours, energy failure and impaired sodium-potassium ATPase activity drive cytotoxic edema, redistributing water into cells. As ionic gradients establish across an initially intact blood-brain barrier, additional water is drawn into the lesion, and only later, with progressive barrier breakdown, does a vasogenic component contribute substantially to mass displacement. Early recanalization, the authors argue, may interrupt this sodium-driven water influx while ionic edema still predominates, before vasogenic swelling becomes established. In severely injured tissue with advanced barrier disruption, however, reperfusion may transiently accentuate capillary leakage, which likely explains the early shift increases observed in some trial analyses that were no longer evident at later time points.

Beyond explaining benefit, the study delivers a practical tool for anticipation. Using ten pre-specified admission variables, the team built a parsimonious prognostic model for mass effect that retained just two parameters: lower baseline ASPECTS, reflecting more advanced ischemic injury on the admission CT, and higher admission plasma glucose, a marker of metabolic stress. Each one-point decrease in ASPECTS raised the odds of mass effect, as did each increment in glucose. On 500-iteration bootstrap internal validation, the two-variable model achieved an optimism-corrected area under the curve of 0.82 with good calibration, meaning that any emergency department, regardless of resources, can identify at the bedside which large-core stroke patients face the greatest risk of dangerous swelling. This supports individualized intensification of neurological monitoring, earlier repeat imaging, and prompt escalation to osmotherapy or decompressive hemicraniectomy in high-risk patients.

Subgroup analyses reinforced the coherence of the findings. The treatment effect remained directionally consistent across age, severity, collateral status, and ASPECTS strata, with formal interaction testing non-significant for all stratifying variables. In the ASPECTS 3-5 subgroup, thrombectomy was associated with substantially lower odds of mass effect and a higher likelihood of favorable outcome, concordant with the edema-mediated pathway mainly present in patients with salvageable tissue. In the ultra-low ASPECTS 0-2 stratum, point estimates were directionally consistent but markedly imprecise, a limitation the authors attribute to underpowering rather than evidence of effect modification. The benefits were obtained in patients selected without advanced perfusion imaging, supporting the pragmatic applicability of an NCCT-CTA pathway as thrombectomy capacity expands in resource-limited regions, where a substantial proportion of the global stroke burden is treated.

The authors are careful about the boundaries of their claims. This was a single-center, non-randomized study in which treatment allocation rested with treating clinicians, and residual confounding by indication cannot be excluded. Mediation analysis in observational data rests on identification assumptions, most importantly the absence of unmeasured confounding of the mediator-outcome relationship, and proportions mediated should be regarded as approximate, model-dependent indicators rather than precise causal quantities. The midline shift endpoint is a late and indirect surrogate whose expression depends on intracranial reserve, and earlier stages of edema captured by quantitative net water uptake were not measured. Still, the convergence of this bedside-accessible estimate with trial-based analyses using sophisticated quantitative biomarkers strengthens the interpretation that preventing malignant swelling is a real and clinically meaningful component of thrombectomy’s benefit. Whether pairing clot removal with standardized edema-targeted management, including optimized glucose and blood pressure control, or adjunctive anti-edema agents such as intravenous glibenclamide and the neuroprotective ApTOLL, further improves outcomes remains to be tested prospectively. For now, the message for clinicians is concrete: roughly one-third of thrombectomy’s power to rescue patients from the gravest strokes operates through keeping the injured brain from swelling to the point of self-destruction, and two routinely available admission numbers can flag who needs the closest watch.

Subject of Research: Thrombectomy improves functional outcome in large core stroke partly by preventing severe cerebral edema: a real-world mediation analysis

Article Title: Thrombectomy improves functional outcome in large core stroke partly by preventing severe cerebral edema: a real-world mediation analysis

Article References: Le, T. Q., Nguyen, S. V. D., Pham, T. P., Tran, T. V., Nguyen, T. Q., Yahanda, A. T., Dmytriw, A. A., Huynh, V. T., Duong, H. Q., Nguyen, T. T., & Le, N. D. (2026). Thrombectomy improves functional outcome in large core stroke partly by preventing severe cerebral edema: a real-world mediation analysis. Frontiers in Neurology, 17, Article 1936247. https://doi.org/10.3389/fneur.2026.1936247

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1936247

Keywords: Thrombectomy, improves, functional, outcome, large, core, stroke, partly, preventing, severe, cerebral, edema

A new retrospective cohort study published in Neurocritical Care suggests that access to that comfort-focused care is far from equal. Analyzing seven years of national hospitalization data, researchers found that among patients who died after mechanical thrombectomy for stroke, Black and Hispanic patients were significantly less likely than white patients to receive a palliative care encounter, and patients from lower-income neighborhoods faced lower odds as well. The disparities compounded each other: low-income Black and Hispanic patients had roughly half the odds of receiving palliative care compared with their white counterparts.

The research team, led by Solomon Kim, Beshoy Saad, and For-Shing Lui of California Northstate University, drew on the National Inpatient Sample, the largest publicly available all-payer hospital database in the United States, covering the years 2016 through 2022. They identified adults aged 18 and older who underwent mechanical thrombectomy for acute ischemic stroke and died during the same hospitalization. After applying the database’s survey weights, the sample of 4,495 patients represented approximately 22,000 people nationwide, with a mean age of 72.5 years and a nearly even sex split at 49.3 percent female.

Palliative care receipt was identified using the ICD-10-CM code Z51.5, the administrative marker for an encounter with palliative care services. Overall, 63.5 percent of patients who died after thrombectomy received such an encounter. But the headline number concealed deep divisions. Among white patients, 66.8 percent received palliative care; among Hispanic patients, 55.1 percent; and among Black patients, only 51.9 percent. That fifteen-point gap between white and Black patients represents thousands of families over the study period who may have faced the death of a loved one without the symptom management, communication support, and decision-making guidance that palliative care teams provide.

To isolate the effect of race and ethnicity from other factors, the researchers used survey-weighted multivariable logistic regression, adjusting for age, sex, insurance status, income, and calendar year. Even after these statistical controls, Black patients had 41 percent lower odds of receiving palliative care than white patients, an adjusted odds ratio of 0.59 with a 95 percent confidence interval of 0.48 to 0.74. Hispanic patients had 36 percent lower odds, with an adjusted odds ratio of 0.64 and a confidence interval of 0.49 to 0.82. Socioeconomic geography mattered independently: patients living in ZIP codes in the lowest quartile of median household income had 18 percent lower odds of receiving palliative care than those in the highest quartile, an adjusted odds ratio of 0.82.

The most striking finding emerged from the study’s intersectional analysis, which examined race and income together rather than separately. Low-income Black and Hispanic patients had an adjusted odds ratio of 0.50, meaning their odds of receiving a palliative care encounter were half those of white patients. This pattern suggests that the disadvantages do not simply add together but interact, with socioeconomic deprivation amplifying racial inequities in end-of-life care. The authors report that the results remained robust across multiple sensitivity analyses, strengthening confidence that the associations are not statistical artifacts.

Why would such gaps exist in the high-technology setting of a neurointerventional suite? The study cannot answer that question directly, because administrative billing data record what happened but not why. The authors point to several plausible mechanisms documented in the broader literature. Palliative care referral depends partly on clinician judgment, and studies of implicit bias in healthcare professionals suggest that unconscious assumptions can shape which patients are offered conversations about goals of care. Cultural factors also play a role: research on end-of-life decision-making among racially and ethnically diverse groups has documented differences in preferences, in trust toward the medical system, and in exposure to information about hospice and palliative services, all of which can influence whether families accept a referral when one is offered.

Structural factors likely contribute as well. Hospitals serving predominantly minoritized and lower-income communities may have less access to palliative care consult teams, particularly outside large academic centers. Prior studies have estimated that a substantial fraction of intensive care unit patients who might benefit from palliative care never receive a consultation, and trigger-based models of need consistently identify more candidates than are actually referred. Insurance status, which the study adjusted for, is only one dimension of access; the availability of palliative services within a given hospital and the staffing of those services vary enormously across the American healthcare landscape.

The stakes are high because palliative care is not merely a courtesy at the end of life. Randomized trials in oncology, including the influential ENABLE III study and Temel and colleagues’ landmark trial of early palliative care in metastatic lung cancer, have shown that palliative involvement can improve quality of life, mood, and in some cases survival, while systematic reviews and meta-analyses have documented benefits for both patients and caregivers. Stroke presents a particularly acute version of the problem, because the decline after a devastating brain injury often follows an unpredictable trajectory that neurologists have called the fourth trajectory of serious illness, blending elements of sudden crisis and prolonged decline. The American Heart Association and American Stroke Association have issued dedicated statements on palliative and end-of-life care in stroke, underscoring that comfort-focused care is an integral part of stroke medicine rather than an admission of failure.

The authors are careful about the limits of their evidence. Because the National Inpatient Sample is administrative, the Z51.5 code may undercount or misclassify palliative care encounters, and the observational design precludes causal conclusions; the associations they report could reflect differences in patient or family preferences, hospital resources, clinician behavior, or unmeasured clinical severity. Still, the consistency and magnitude of the findings, particularly the halving of odds among low-income minority patients, argue that something systematic is at work. The study’s data are publicly available through the Healthcare Cost and Utilization Project, and the analysis code has been shared openly, inviting replication and extension. What the researchers call for next is investigation into modifiable contributors, the levers that hospitals and health systems can actually pull: standardized palliative care triggers for high-mortality procedures, clinician education on equitable goals-of-care conversations, and investment in consult services at hospitals that currently lack them. As mechanical thrombectomy continues to expand to more hospitals and longer treatment windows, ensuring that its occasional failures are met with equal compassion, regardless of a patient’s race or ZIP code, becomes a measure of whether stroke medicine’s remarkable technical progress is matched by progress in its humanity.

Subject of Research: Racial and socioeconomic disparities in palliative care use among patients dying after mechanical thrombectomy for acute ischemic stroke

Article Title: Racial and Socioeconomic Disparities in Palliative Care Utilization Among Patients with In-Hospital Mortality After Mechanical Thrombectomy for Stroke

Article References: Kim, S., Saad, B., & Lui, F.-S. (2026). Racial and Socioeconomic Disparities in Palliative Care Utilization Among Patients with In-Hospital Mortality After Mechanical Thrombectomy for Stroke. Neurocritical Care. https://doi.org/10.1007/s12028-026-02636-7

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02636-7

Keywords: stroke, mechanical thrombectomy, palliative care, health disparities, end-of-life care, neurocritical care, National Inpatient Sample, health equity, acute ischemic stroke, socioeconomic status, racial disparities, Racial

The review, led by Yuxiang Li and Zhigang Mei of Hunan University of Chinese Medicine together with colleagues, takes stock of why endovascular therapy (EVT), which has revolutionized treatment of large vessel occlusion, still leaves a substantial proportion of patients disabled. The authors identify four interlocking challenges: the narrow therapeutic time window during which treatment must begin, suboptimal patient selection, difficulty achieving a first-pass effect in which the clot is removed on the initial attempt, and futile reperfusion—the situation in which blood flow is restored to tissue that can no longer benefit from it.

Futile reperfusion is the review’s central villain, and it wears several faces. The no-reflow phenomenon prevents blood from penetrating the downstream microvasculature even after the main artery is cleared. Reocclusion can shut the vessel again. Ischemia-reperfusion injury means that the very act of restoring blood flow unleashes a cascade of reactive oxygen species, inflammatory signaling, and damage-associated molecular patterns that injure the tissue they were meant to save. On top of these come hemorrhagic transformation, in which the damaged blood-brain barrier gives way to bleeding into the infarcted tissue, and malignant cerebral edema, the catastrophic swelling that can compress the brain fatally within days.

To combat these failures, the authors begin with diagnosis. Multimodal neuroimaging—combining non-contrast CT, diffusion-weighted imaging, CT or MR angiography, perfusion imaging, and collateral status assessment—now allows clinicians to distinguish patients whose brain tissue is salvageable from those in whom intervention would be futile. The review highlights how predictive biomarkers and artificial intelligence are being layered onto these imaging modalities to refine prognostic prediction and sharpen patient selection criteria. Machine learning models trained on large imaging datasets can, in principle, quantify the ischemic core, estimate penumbral salvage tissue, and predict the likelihood of functional independence on the modified Rankin Scale with a speed and consistency that human readers cannot match in the middle of the night.

The second pillar of the proposed strategy is cerebral cytoprotection, a concept that has had a checkered history in stroke research but is now being reinvigorated by mechanistic insights. Rather than attempting to rescue neurons with a single magic bullet, the emerging generation of cytoprotective strategies aims to stabilize brain energy metabolism across the entire neurovascular unit. The review describes interventions that shore up mitochondrial function, the cellular power plants whose failure during ischemia triggers programmed cell death; that preserve the endothelial glycocalyx, the delicate sugar-rich layer lining brain microvessels that prevents leukocytes and platelets from clogging capillaries; and that protect pericytes, the contractile cells wrapped around capillaries whose death contributes to the no-reflow phenomenon.

Notably, the authors argue that effective cytoprotection could do more than reduce injury—it could extend the therapeutic time window itself. If brain cells can be kept metabolically viable for longer while the artery remains blocked, the hard six-hour boundaries that currently govern treatment decisions might become more flexible, allowing patients who arrive late to hospitals to still benefit from mechanical thrombectomy. The review also points to preclinical evidence supporting the targeting of the glymphatic system, the brain’s waste-clearance network driven by cerebrospinal fluid flow through perivascular channels, which depends heavily on aquaporin-4 channels and may influence edema resolution and reperfusion recovery.

The third pillar concerns the endovascular procedure itself. The review surveys device innovations in stent retrievers and aspiration catheters designed to improve the first-pass effect, since each additional pass of a device through the vessel increases the risk of endothelial damage, distal embolization, and vasospasm. It also examines optimized bridging thrombolysis strategies, weighing intravenous thrombolysis with tissue-type plasminogen activator against the newer agent tenecteplase, which offers greater fibrin specificity and easier administration. Tailored adjuvant antithrombotic regimens—balancing the prevention of reocclusion against the risk of hemorrhagic transformation—round out the peri-procedural toolkit, with particular attention to patients with intracranial atherosclerotic stenosis, in whom standard approaches often fall short.

Underlying all of this is a sobering assessment of why so many promising therapies have failed to translate from bench to bedside. The review is candid that preclinical models, particularly the middle cerebral artery occlusion model in rodents, are oversimplified relative to the heterogeneous, comorbidity-laden human stroke population. Young, healthy laboratory animals with standardized infarcts respond to cytoprotective agents in ways that elderly diabetic patients with hypertension, atrial fibrillation, and atherosclerotic disease simply do not. The absence of patient stratification for tailored cytoprotection is identified as a critical gap: a therapy that stabilizes mitochondria may help one subgroup while doing nothing—or harm—for another, and without precision biomarkers to identify who should receive what, trials are doomed to average out to null results.

The authors also emphasize the systemic dimension of peri-procedural care. Blood pressure management, collateral circulation support, remote ischemic conditioning, and even neuromodulation approaches such as cathodal transcranial direct current stimulation appear in the synthesis as adjuncts that may influence outcomes. The unifying theme is that stroke treatment does not end when the clot is extracted; the hours surrounding the procedure, from prehospital triage through intensive care monitoring, constitute a continuous therapeutic opportunity that current practice fragments into disconnected episodes.

What emerges from the review is a vision of stroke medicine in which successful recanalization is treated as a necessary but insufficient condition for recovery. In this vision, artificial intelligence-assisted imaging selects the right patient at the right time, cytoprotective regimens keep the endangered brain metabolically alive while the interventionalist works, refined devices clear the vessel in a single pass, and microvascular- and glymphatic-targeted therapies ensure that restored blood flow actually nourishes tissue rather than igniting inflammation. The authors are careful to frame these as directions warranting further investigation rather than established practice, and they call for optimized preclinical models and precision biomarkers to close the translation gap. But their core message is clear: the era of celebrating recanalization alone is ending, and the next chapter of acute ischemic stroke treatment will be written in the integration of technologies that protect the brain as vigorously as they unblock it.

Subject of Research: Integrated neuroimaging, cytoprotection, and endovascular strategies for improving outcomes in acute ischemic stroke

Article Title: Beyond recanalization: integrating neuroimaging, cytoprotection and endovascular strategies in acute ischemic stroke

Article References: Li, Y., Sun, F., Zhao, L., Wu, B., Xiong, H., Zhou, Y., Zhang, W., & Mei, Z. (2026). Beyond recanalization: integrating neuroimaging, cytoprotection and endovascular strategies in acute ischemic stroke. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08981-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08981-7

Keywords: acute ischemic stroke, endovascular therapy, futile reperfusion, cerebral cytoprotection, neuroimaging, artificial intelligence, mechanical thrombectomy, no-reflow phenomenon, reperfusion injury, glymphatic system, large vessel occlusion, patient selection

The study drew on the German Stroke Registry–Endovascular Treatment (GSR-ET), a prospective, multicenter registry spanning 25 comprehensive stroke centers across Germany. Between June 2015 and December 2023, more than 18,000 patients were screened, and after excluding those with extracranial carotid occlusions, pre-stroke disability, or missing key clinical data, 5,448 patients treated with mechanical thrombectomy for anterior circulation strokes formed the analytical cohort. The mean age was 71.2 years, 48 percent were women, and the median stroke severity on admission, measured by the National Institutes of Health Stroke Scale (NIHSS), was 13. The researchers stratified patients into nine subgroups based on admission NIHSS (0–10, 11–15, or ≥16) and the Alberta Stroke Program Early CT Score (ASPECTS), a ten-point measure of early infarct signs on CT imaging (10, 8–9, or ≤7).

This dual stratification was designed to capture what neurointerventionalists call clinical-core mismatch. The concept is elegant: a patient whose neurological deficit is dramatically worse than the visible extent of infarction likely has a large penumbra, a zone of struggling but still salvageable brain tissue, whereas a patient whose symptoms are mild relative to a large established infarct has less to gain from reopening the vessel. The DAWN and DEFUSE-3 trials famously demonstrated that patients with pronounced mismatch benefit from thrombectomy even in extended time windows of up to 24 and 16 hours, respectively. But those trials used sophisticated perfusion imaging and volumetric core measurements. The new study instead used the readily available NIHSS and ASPECTS scores as a clinical surrogate, testing whether the same pattern holds in the messy reality of routine practice.

The results were striking. Reperfusion success was graded using the modified Thrombolysis in Cerebral Infarction (mTICI) scale: 650 patients achieved minimal or no reperfusion (mTICI 0–2a), 1,873 achieved partial reperfusion (mTICI 2b), and 2,925 achieved complete recanalization (mTICI 3). Unadjusted outcomes followed a steep gradient: only 20 percent of patients with failed reperfusion achieved functional independence, defined as a modified Rankin Scale (mRS) score of 0 to 2 at 90 days, compared with 46 percent after partial reperfusion and 54 percent after complete recanalization. Mortality at 90 days told the same story in reverse, at 39 percent, 20 percent, and 17 percent respectively. Symptomatic intracranial hemorrhage, a feared procedural complication, occurred in 5 percent of failed reperfusion cases but only 2 percent of complete recanalizations.

Because patients who achieve full recanalization may differ systematically from those who do not, the researchers applied inverse-probability-weighted regression adjustment (IPWRA), a double-robust statistical technique that controls for confounders such as age, sex, comorbidities, baseline NIHSS and ASPECTS, intravenous thrombolysis, and the number of retrieval attempts. The adjusted estimates confirmed the pattern: 25 percent good outcomes after mTICI 0–2a, 46 percent after mTICI 2b, and 52 percent after mTICI 3, with adjusted mean mRS scores of 4.0, 3.0, and 2.7 respectively. Crucially, significant benefit from successful reperfusion was observed in every one of the nine NIHSS-ASPECTS subgroups, including patients with large established infarcts and those with only mild symptoms.

The size of that benefit, however, varied dramatically. The clearest beneficiaries were patients with high clinical-core mismatch, particularly those with a perfect ASPECTS of 10 and severe deficits (NIHSS ≥16). In this group, only 9 percent of patients with failed reperfusion achieved functional independence, compared with 47 percent after complete recanalization, an absolute difference of 38 percentage points. Patients with moderate deficits (NIHSS 11–15) and ASPECTS 10 showed comparable gains. At the opposite extreme, patients with severe deficits and extensive infarct signs (NIHSS ≥16, ASPECTS ≤7) saw a much smaller but still significant benefit, with good outcomes rising from 12 percent to 23 percent, an absolute difference of 11 percentage points. The exploratory mRS shift analysis reinforced the pattern, showing the largest disability reduction, nearly two full mRS points, in the ASPECTS 10 and NIHSS 11–15 subgroup.

One of the most clinically consequential findings concerned the difference between near-complete and complete reperfusion. Pushing from mTICI 2b to mTICI 3 often requires additional retrieval attempts, each carrying a risk of vessel perforation, dissection, or distal clot migration. The data showed that the extra benefit of full recanalization was concentrated in high-mismatch patients: in the NIHSS ≥16, ASPECTS 10 subgroup, complete recanalization lifted good outcomes from 32 percent to 47 percent, a 15-point gain. But in patients with large infarcts (NIHSS ≥16, ASPECTS ≤7), outcomes were essentially identical after mTICI 2b and mTICI 3, both around 20 percent. The authors suggest that in selected low-mismatch cases, accepting mTICI 2b as an adequate procedural endpoint may be a pragmatic choice that avoids unnecessary procedural risk.

The findings also complicate the emerging picture from randomized trials. Recent studies such as SELECT2, ANGEL-ASPECT, RESCUE-Japan LIMIT, and TENSION demonstrated that even patients with large established infarcts benefit from thrombectomy, expanding treatment beyond the classic mismatch paradigm. Meanwhile, a post-hoc analysis of ANGEL-ASPECT failed to show benefit in patients stratified by clinical-radiological mismatch, and recent trials in distal medium vessel occlusions have questioned whether mismatch concepts translate uniformly across vascular territories. The new registry data reconcile some of this tension: mismatch profiles appear to modify the size of the treatment effect rather than determine whether treatment helps at all. In other words, clinical-core mismatch should inform expectations and procedural goals, not serve as a rigid gatekeeper for eligibility.

The authors are careful to note important limitations. Roughly 70 percent of screened patients were excluded in the complete-case analysis because of missing variables, a substantial selection process that may bias effect estimates and limit generalizability to unselected populations. Patients with pre-stroke disability were excluded, local investigators rather than a central core lab graded ASPECTS and mTICI, and unmeasured factors such as collateral circulation, infarct location, and time from onset to imaging could not be fully accounted for. The use of linearized mRS scores in exploratory analyses also assumes equal spacing between scale points, an assumption that may not fully hold. These caveats mean the findings in mild stroke and low-ASPECTS groups should be considered exploratory, even as the high-mismatch results align closely with prior randomized evidence.

Looking forward, the study points toward a more individualized era of stroke treatment. Rather than fixed subgroup thresholds, the authors argue that outcome effects across ASPECTS likely follow a continuous gradient, and future selection tools may integrate advanced imaging biomarkers such as net water uptake, a quantitative measure of early brain swelling, to estimate each patient’s likely benefit from reperfusion. For now, the message for clinicians is nuanced but actionable: successful reperfusion helps virtually every patient profile, but the magnitude of benefit is greatest when a severe deficit signals a large salvageable penumbra, and the pursuit of complete recanalization matters most precisely in those patients. In resource-limited settings where every thrombectomy counts, that distinction could help ensure the right patients receive the most aggressive endovascular effort.

Subject of Research: Reperfusion-dependent outcomes after endovascular thrombectomy for acute ischemic stroke, stratified by NIHSS-ASPECTS clinical-core mismatch

Article Title: Reperfusion‐Dependent Outcomes After Endovascular Thrombectomy Stratified by NIHSS‐ASPECTS Clinical‐Core Mismatch

Article References: Schlicht, F., Meyer, L., Broocks, G., Bechstein, M., Thaler, C., Heitkamp, C., Winkelmeier, L., Geest, V., Heitkamp, A., Jungnitz, M., Peter, G., Meucci, L., Faizy, T., Nawabi, J., Brekenfeld, C., Flottmann, F., Schell, M., Hadjilaou, A., Hanning, U., … German Stroke Registry Endovascular Treatment (2026). Reperfusion‐Dependent Outcomes After Endovascular Thrombectomy Stratified by NIHSS ‐ ASPECTS Clinical‐Core Mismatch. Annals of Clinical and Translational Neurology, 13(9), 1807-1816. https://doi.org/10.1002/acn3.70358

Image Credits: AI Generated

DOI: 10.1002/acn3.70358

Keywords: mechanical thrombectomy, acute ischemic stroke, reperfusion, clinical-core mismatch, NIHSS, ASPECTS, mTICI, functional outcome, German Stroke Registry, large vessel occlusion, penumbra, neurointervention

Mechanical thrombectomy, in which physicians thread catheters through blood vessels to physically remove a clot, is the established standard of care for acute ischemic stroke caused by a large vessel occlusion. Intravenous thrombolysis with the drug alteplase is recommended as first-line therapy within four and a half hours of symptom onset, and beyond that window when perfusion imaging shows salvageable brain tissue. When both treatments are used, the combination is known as bridging therapy. Yet the practice remains debated, because intravenous thrombolysis carries a risk of hemorrhage, and well-designed trials comparing direct thrombectomy with bridging therapy have produced mixed results. A recent Cochrane systematic review pooling six randomized controlled trials found no evidence of a difference in functional outcome, mortality, or intracranial hemorrhage between the two strategies, and its authors called for research into time- and person-specific factors that might determine who benefits from the intravenous drug.

Researchers at University Hospital Carl Gustav Carus in Dresden suspected that one such factor might be the biological composition of the clot itself. Clots removed from patients with large vessel occlusion vary considerably in their proportions of fibrin and red blood cells, and these differences fall largely along etiological lines. Clots of cardiac origin, which form when the heart’s rhythm falters and debris travels to the brain, tend to be rich in fibrin and platelets. Clots arising from atherosclerotic disease in the neck or brain arteries tend to be red blood cell rich. Fibrin-rich clots are denser, create more friction against vessel walls, and are known to be less sensitive to thrombolytic drugs, which work by infiltrating the clot and thinning its fibrin fibers. Red blood cell rich clots, with their more loosely packed fibrin networks, allow greater drug penetration and dissolve more readily.

To test whether these biological differences translate into different treatment outcomes, the team conducted a post hoc analysis of their prospective registry of consecutive thrombectomy patients treated between January 2017 and January 2023. The cohort included 798 adults who underwent thrombectomy for anterior circulation large vessel occlusion, either at the Dresden center directly or after transfer from one of thirteen telestroke network spokes or eight partner primary stroke centers in eastern Saxony. Just over half the patients were women, the median age was 77 years, and the median baseline stroke severity on the National Institutes of Health Stroke Scale was 15. Nearly half of the patients, 395 in total, received intravenous alteplase before thrombectomy; no other thrombolytic agents were used during the study period. Stroke etiology was classified according to the TOAST criteria by senior stroke consultants and validated through a secondary central review of all medical records.

The primary outcome was the time from groin puncture to successful angiographic reperfusion, quantified using the modified Thrombolysis in Cerebral Infarction score, with successful reperfusion defined as a score of 2b or higher. The researchers used stratified Cox proportional hazards regression, adjusting for age, baseline stroke severity, tandem occlusions, carotid T occlusions, occlusion site, and distal thrombus migration—a shift of the clot from a proximal to a more distal arterial segment that occurred before any endovascular maneuver. Overall, successful reperfusion was achieved in 85.2 percent of patients, and cardioembolic stroke accounted for 58.9 percent of cases.

The results split cleanly along etiological lines. Among the 330 patients with non-cardioembolic stroke, bridging intravenous thrombolysis was independently associated with a roughly 40 percent higher hazard of achieving successful reperfusion at any point during the procedure, with an adjusted hazard ratio of 1.40. This effect grew stronger in sensitivity analyses: when patients with stroke of undetermined etiology were excluded, the adjusted hazard ratio rose to 2.06, and a sub-analysis restricted to patients with large artery atherosclerotic stroke reproduced the benefit. Consistent with this, patients with atherosclerotic stroke who received the intravenous drug required about 36 percent fewer aspiration attempts during thrombectomy, an effect measured with a negative binomial regression that accounted for age, initial CT severity score, and occlusion site.

Among the 468 patients with cardioembolic stroke, however, the picture was entirely different. Intravenous thrombolysis alone showed no measurable effect on time to reperfusion, with an adjusted hazard ratio of 1.13 that did not reach statistical significance. More troubling, when the clot migrated distally after thrombolysis and before the procedure—a phenomenon observed in 9.7 percent of cardioembolic patients who received the drug versus 0.8 percent of those who did not—the likelihood of successful reperfusion at any given time point dropped by approximately 43 percent, with an adjusted hazard ratio of 0.57. The researchers propose that when thrombolysis fails to soften a fibrin-rich cardiac clot, it may instead promote its displacement into smaller, more distal arterial segments where thrombectomy is technically harder and less effective, a concern underscored by two recent negative randomized trials of thrombectomy for distal vessel occlusions.

The study also quantified the clinical stakes of procedural speed. Each additional 10 minutes of groin-to-recanalization time increased the odds of a worse functional outcome on the modified Rankin scale at 90 days by 8.6 percent, an association that remained robust after adjustment for patient characteristics, stroke features, interventional parameters, and metabolic markers. In other words, a treatment that accelerates reperfusion in one stroke subtype and delays it in another could meaningfully shift outcomes for individual patients, even if population-level averages obscure the difference.

The mechanistic story fits a growing body of evidence. Analyses of the MR CLEAN Registry biobank and other prospective thrombus studies have shown that cardioembolic clots contain a higher proportion of fibrin and platelets, while atherosclerotic clots are predominantly red blood cell rich. Fibrin-rich thrombi demand more recanalization attempts and yield lower reperfusion rates, and laboratory work suggests they are less susceptible to thrombolytic agents because their fibrin is densely packed. The multicenter RESTORE Registry found that clots retrieved in earlier thrombectomy passes had higher red blood cell content, while later passes yielded fibrin-rich material. Beyond simple histology, molecular analyses have identified neutrophil extracellular traps as structural components that stabilize the fibrin network and may contribute to thrombolysis resistance—raising the possibility that partial clot destabilization without effective lysis could promote distal embolization and increase procedural complexity.

The Dresden team is careful to note the limitations of their work. The data come from a regional network registry, histological characterization of retrieved clots was not available, and the subgroup of cardioembolic patients with distal thrombus migration was small, leaving room for residual confounding despite robust statistical adjustment. Cryptogenic stroke, moreover, is a highly heterogeneous category that may mask diverse underlying mechanisms. Still, the consistency of the etiological differences across all multivariable models, and their reproduction in the atherosclerotic sub-analysis, suggest a robust finding. If confirmed in larger studies, the results could help clinicians move beyond a one-size-fits-all approach to bridging therapy, reserving intravenous thrombolysis for the patients whose clots are most likely to yield to it—and sparing others a treatment that may do more harm than good.

Subject of Research: Effect of intravenous thrombolysis before thrombectomy on reperfusion outcomes in cardioembolic versus non-cardioembolic acute ischemic stroke

Article Title: IV Thrombolysis Facilitates Interventional Reperfusion in Non‐Cardioembolic but Not Cardioembolic Stroke

Article References: Sedghi, A., Kaiser, D. P. O., Arndt, M., Diel, N. J., Simon, E., Polanski, W. H., Puetz, V., Huttner, H. B., & Siepmann, T. (2026). IV Thrombolysis Facilitates Interventional Reperfusion in Non‐Cardioembolic but Not Cardioembolic Stroke. Annals of Clinical and Translational Neurology, 13(9), 1893-1902. https://doi.org/10.1002/acn3.70370

Image Credits: AI Generated

DOI: 10.1002/acn3.70370

Keywords: stroke, thrombectomy, intravenous thrombolysis, large vessel occlusion, cardioembolic stroke, clot composition, reperfusion, alteplase, TOAST classification, distal thrombus migration, fibrin-rich thrombi, bridging therapy

The technology’s lineage traces back to the first-generation Merci retriever, a corkscrew-like device approved in the mid-2000s that proved mechanical clot removal in the brain was feasible but achieved only modest recanalization rates. The decisive turning point came with self-expanding stent retrievers, notably Solitaire and Trevo, which are compressed inside a microcatheter, navigated through the vasculature to the clot, and then unsheathed so the nitinol mesh expands and integrates with the thrombus. Unlike a static stent left in place, these retrievers engage the clot mechanically across its full length, allowing the operator to pull the entire construct into a guide catheter. Randomized trials published in 2015, including MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, and REVASCAT, together demonstrated overwhelming benefit of endovascular thrombectomy over medical therapy alone, reshaping international guidelines almost overnight and establishing first-generation stent retrievers as the anchor of modern stroke intervention.

The technical principle behind the second-generation devices is deceptively simple: radial force from the expanding mesh compresses the clot against the vessel wall while individual struts penetrate the thrombus, creating a mechanical interlock. In practice, the interaction is governed by a complex interplay of clot composition, device geometry, and vessel size. Ischemic stroke thrombi vary enormously, from soft, red-cell-rich emboli shed from the heart to hard, fibrin-rich clots loaded with platelets and von Willebrand factor that resist mechanical integration. Histological analyses cited in the review show that fibrin-dense outer shells and platelet-rich regions correlate with failed retrieval and poorer revascularization outcomes. This biological heterogeneity has pushed engineers toward devices with segmented designs, larger mesh cells, and specialized capture zones. Multi-zone platforms such as NeVa incorporate discrete drop zones with tightly spaced struts designed to trap organized clots, while radially adjustable retrievers such as Tigertriever allow the operator to expand the device progressively until it matches the vessel diameter, an advantage in both oversized proximal vessels and narrow distal branches.

Device development has also converged on integrated retrieval-and-protection concepts. EmboTrap-class retrievers feature distal capture baskets intended to intercept fragments that would otherwise migrate downstream and cause new infarcts, a complication known as distal embolization. registries such as ARISE II and the global EXCELLENT registry for the EMBOTRAP device have reported high first-pass reperfusion rates with these hybrid designs. First-pass effect, meaning complete reperfusion achieved in a single retrieval attempt, has emerged as a key performance metric because each additional pass increases procedural time, trauma to the endothelium, and the risk of hemorrhagic transformation. Recent generation devices such as Solitaire X have demonstrated significantly improved first-pass success compared with their predecessors, and tip-design studies confirm that the shape and stiffness of the retriever’s distal end materially influence whether fragments escape during withdrawal.

In parallel with hardware evolution, procedural technique has advanced into highly choreographed combinations. The most influential refinement is the pairing of stent retrievers with large-bore aspiration catheters positioned at the face of the clot, a strategy variously branded as Solumbra, SAVE, or ARTS. Aspiration continuously extracts clot fragments dislodged by the retriever, reducing the shower of emboli that would otherwise travel into healthy territory. Balloon guide catheters add a second layer of protection by temporarily arresting antegrade flow in the parent artery, creating a stagnant zone from which debris can be vacuumed rather than washed distally. The randomized PROTECT-MT trial from China showed that balloon guide catheters significantly improve excellent reperfusion rates, validating what in-vitro flow studies had long predicted. For refractory occlusions, operators increasingly deploy double stent retrievers simultaneously, doubling the mechanical interface with the clot, and recent bench studies plus the randomized TWIN2WIN trial support this bail-out strategy, although cumulative vessel wall injury remains a documented concern in animal models.

The clinical indications for thrombectomy have expanded dramatically alongside the devices themselves. Landmark trials including DAWN and DEFUSE 3 extended the treatment window from six hours to twenty-four hours in patients selected by advanced perfusion imaging, demonstrating that brain tissue can remain salvageable long after symptom onset when collateral circulation is robust. More recently, attention has turned to posterior circulation strokes caused by basilar artery occlusion, which are uniformly devastating without treatment; trials such as ATTENTION and BAOCHE provided the first randomized evidence supporting endovascular therapy in this territory. Equally consequential are the new studies in large infarct cores, including SELECT2, ANGEL-ASPECT, and RESCUE-Japan LIMIT, which overturned the long-held exclusion of patients with extensive established damage and showed net functional benefit from thrombectomy even in these high-risk presentations.

The most recent frontier involves medium and distal vessel occlusions, blocks in arteries one to three millimeters in diameter that were historically managed with medication because standard devices were too bulky. Purpose-built low-profile retrievers, including 3-millimeter variants of Solitaire X and Trevo and the adjustable Tigertriever 13, have enabled operators to reach these small vessels, and a wave of randomized trials in 2025 and 2026, including DISTALS, DISTAL, and DISCOUNT, has begun to establish benefit under imaging-guided selection. The review emphasizes that territory-specific engineering, from smaller delivery profiles to softer, more flexible distal architectures, is now the dominant axis of device innovation, with hybrid devices such as Aperio and specialized platforms for cerebral venous sinus thrombosis broadening the field further.

Materials science is contributing a quieter but potentially transformative layer of progress. Nitinol remains the workhorse alloy because its superelasticity allows dense crimping and atraumatic self-expansion, but its poor radiographic visibility complicates positioning, prompting coatings and design changes that enhance fluoroscopic contrast. Surface engineering aims to reduce thrombogenicity and endothelial damage, with heparin-based hydrogel coatings, endothelium-mimicking bioactive layers, and nanostructured oxide films under investigation. More provocative are clot-adhesive coatings that deliberately bind to fibrin, effectively welding the retriever to resistant thrombi, and micro-patterned surfaces that increase contact area. In a striking departure from conventional designs, milli-spinner thrombectomy, reported in Nature in 2025, uses a rotating, tangle-forming structure to compress and extract clots regardless of composition, hinting that the retrieval paradigm itself may not be permanent.

Looking forward, the review identifies thrombus characterization as the bridge between biology and device choice. Radiomic analysis of clot appearance on imaging, combined with biomarkers of clot composition, could soon allow operators to predict before the first pass whether a given occlusion will yield to a standard retriever or demand an adjustable device, dual-stent technique, or direct aspiration. Personalized device selection of this kind would attack the core unresolved problems: fibrin-rich resistant thrombi, embolic complications, vascular injury from repeated passes, and the limited high-level evidence supporting many of the newest devices, which have largely been validated in registries rather than randomized trials. The authors argue that ongoing integration of engineering innovation with rigorous clinical data will support increasingly individualized and safer thrombectomy strategies, and with stroke remaining a leading cause of disability globally, even incremental gains in first-pass success translate into meaningful reductions in death and dependence. The stent retriever, born from a simple wire mesh, continues to evolve into a precision instrument tailored to the specific clot, vessel, and patient standing between a stroke and recovery.

The stakes of these technical refinements are best understood against the sheer scale of the disease. Global burden analyses cited in the review estimate that stroke affected well over a hundred million people worldwide in recent years, and large vessel occlusions contribute disproportionately to death and dependence because the entire territory of a major cerebral artery is threatened within minutes of onset. Intravenous thrombolysis, the other pillar of acute reperfusion therapy, dissolves clot biochemically but achieves recanalization in only a minority of large vessel occlusions and carries a risk of arterial reocclusion, which is why mechanical retrieval became indispensable.

The review also situates current practice within the 2026 American Heart Association and American Stroke Association guideline for early management of acute ischemic stroke, reflecting how trial evidence is rapidly codified into standards of care. Beyond the procedure itself, the authors note that reperfusion initiates a second wave of injury, including blood-brain barrier breakdown and neuroinflammation, meaning that restoring flow is necessary but not always sufficient for good functional recovery. This biological reality underscores why procedural metrics such as first-pass success and reduced embolization matter clinically, and why the field increasingly views mechanical thrombectomy not as an isolated engineering problem but as one component of a broader effort spanning imaging selection, device design, and post-reperfusion neuroprotection.

Subject of Research: Technological advances and clinical applications of stent retrievers in endovascular thrombectomy for acute ischemic stroke.

Article Title: Stent retrievers for acute ischemic stroke: technological advances, clinical applications, and future perspectives

Article References: Xie, Z., Wang, Z., Fu, P., Shi, Z., Zhuang, Z., Wang, H., Xiang, Y., Yin, X., & Chen, Z. (2026). Stent retrievers for acute ischemic stroke: technological advances, clinical applications, and future perspectives. Journal of Neurology, 273(10), Article 590. https://doi.org/10.1007/s00415-026-14126-z

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14126-z

Keywords: acute ischemic stroke, stent retriever, mechanical thrombectomy, large vessel occlusion, endovascular treatment, first-pass reperfusion, nitinol, distal embolization, balloon guide catheter, medium vessel occlusion, thrombus composition, reperfusion